Study Details

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de novo Kidney Transplant Recipients

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02921789

Astellas Study ID

The unique identification code given by the study sponsor.

7163-CL-3201

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Condition

Kidney Transplants, Kidney Scarring Disease

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female & Male

Product

bleselumab

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

May 2017 - May 2021

Masking

None (Open Label)

Enrollment number

67

A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de novo Kidney Transplant Recipients

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de novo Kidney Transplant Recipients? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

University of Pennsylvania Health System, PCAM

Philadelphia, United States, 19104

Pinnacle Health

Harrisburg, United States, 17104

University of Alabama at Birmingham

Birmingham, United States, 35294

Site CA15002

Edmonton, Canada, TG6 2B7

Swedish‐Medical Center

Seattle, United States, 98104

Site CA15005

Vancouver, Canada, V6Z 1Y6

Tampa General Hospital

Tampa, United States, 33606

Medical University of South Carolina

Charleston, United States, 29425

Baylor All Saints Medical Center

Ft. Worth, United States, 76104

Erie County Medical Center

Buffalo, United States, 14215

Tulane University Health Service Center

New Orleans, United States, 70112

Integris/Nazih Zudhi Transplant Institute

Oklahoma City, United States, 73112

Baylor University Medical Center

Dallas, United States, 75246

Montefiore Medical Center

Bronx, United States, 10467

University of Utah Medical Center

Salt Lake City, United States, 84132

Columbia University Medical Center

New York, United States, 10032

Augusta University/Georgia Regents

Augusta, United States, 30912

Site CA15003

Vancouver, Canada, V6Z 1Y6

University of Louisville

Louisville, United States, 40202

University of Colorado

Aurora, United States, 80045

University of Pittsburgh Medical Center

Pittsburgh, United States, 15213

UCSF

San Francisco, United States, 94143

University of North Carolina

Chapel Hill, United States, 27713

Indiana University

Indianapolis, United States, 46220

University of Illinois, Chicago

Chicago, United States, 60612

California Pacific Medical Center

San Francisco, United States, 94115

Northwestern University

Chicago, United States, 60611

Methodist Hospital, The

Houston, United States, 77030

Mount Sinai, Icahn School of Medicine

New York, United States, 10029

Washington University in St. Louis

St. Louis, United States, 63110

Michigan Medicine

Ann Arbor, United States, 48109

University of Chicago

Chicago, United States, 60637

University of Miami

Miami, United States, 33136

Site CA15006

Montreal, Canada, H1T 2M4

Stanford School of Medicine

Palo Alto, United States, 94304

University of Virginia

Charlottesville, United States, 22908

Duke University Medical Center

Durham, United States, 27710

University of Arizona

Tucson, United States, 85724

NYU Transplant Institute

New York, United States, 10016

University of Maryland

Baltimore, United States, 21201

NY Presybyterian Hosp – Cornell University

New York, United States, 10065

St. Barnabas

Livingston, United States, 07039